| Project/Area Number |
23659624
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
SAJI Shigehira 京都大学, 医学(系)研究科(研究院), 准教授 (80446567)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HONMA Naoko 東京都健康長寿医療センター研究所, 研究員 (70321875)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | エストロゲン受容体 / 乳がん / ホルモン療法 / タモキシフェン |
|---|
| Research Abstract |
Estrogen Receptor (ER) α -negative, Progesterone Receptor(PR)-negative and Her2-negative breast cancer has been known as Triple-negative breast cancer (TNBC), and has poor prognosis. Subset of TNBC express second ER named ERβ, and we reported that these patients might have benefit from tamoxifen treatment. Here we showed that ERβ-nagative TNBC might have unfavorable effect from tamoxifen, and androgen receptor expression and serum concentration of androgen metabolite seemed to have important role in the ERβ-positive TNBC. Further studies including these factors would be warranted for the future clinical trial of this strategy.
|
